Rexmyelocel T

Drug Profile

Rexmyelocel T

Alternative Names: BM-MNCs - Rexgenero; REX-001

Latest Information Update: 08 Aug 2016

Price : $50

At a glance

  • Originator Rexgenero
  • Class
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Peripheral ischaemia

Most Recent Events

  • 07 Jul 2016 Phase-III clinical trials in Peripheral ischaemia in Spain (Intra-arterial) (EudraCT2016-000240-34)
  • 14 Apr 2016 The UK Medicines and Healthcare Products Regulatory Agency (MHRA) grants Promising Innovative Medicine Designation (PIM) for Rexmyelocel-T for the treatment of Peripheralischemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top